Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia.
Saez-Ayala M, Hoffer L, Abel S, Ben Yaala K, Sicard B, Andrieu GP, Latiri M, Davison EK, Ciufolini MA, Brémond P, Rebuffet E, Roche P, Derviaux C, Voisset E, Montersino C, Castellano R, Collette Y, Asnafi V, Betzi S, Dubreuil P, Combes S, Morelli X. Saez-Ayala M, et al. Among authors: castellano r. Nat Commun. 2023 May 29;14(1):3079. doi: 10.1038/s41467-023-38668-2. Nat Commun. 2023. PMID: 37248212 Free PMC article.
Active transcription of the human FASL/CD95L/TNFSF6 promoter region in T lymphocytes involves chromatin remodeling: role of DNA methylation and protein acetylation suggest distinct mechanisms of transcriptional repression.
Castellano R, Vire B, Pion M, Quivy V, Olive D, Hirsch I, Van Lint C, Collette Y. Castellano R, et al. J Biol Chem. 2006 May 26;281(21):14719-28. doi: 10.1074/jbc.M602373200. Epub 2006 Apr 4. J Biol Chem. 2006. PMID: 16595663 Free article.
Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.
Veuillen C, Aurran-Schleinitz T, Castellano R, Rey J, Mallet F, Orlanducci F, Pouyet L, Just-Landi S, Coso D, Ivanov V, Carcopino X, Bouabdallah R, Collette Y, Fauriat C, Olive D. Veuillen C, et al. Among authors: castellano r. J Clin Immunol. 2012 Jun;32(3):632-46. doi: 10.1007/s10875-011-9624-5. Epub 2012 Feb 9. J Clin Immunol. 2012. PMID: 22318393
Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL.
Loosveld M, Castellano R, Gon S, Goubard A, Crouzet T, Pouyet L, Prebet T, Vey N, Nadel B, Collette Y, Payet-Bornet D. Loosveld M, et al. Among authors: castellano r. Oncotarget. 2014 May 30;5(10):3168-72. doi: 10.18632/oncotarget.1873. Oncotarget. 2014. PMID: 24930440 Free PMC article.
Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia.
Collette Y, Prébet T, Goubard A, Adélaïde J, Castellano R, Carbuccia N, Garnier S, Guille A, Arnoulet C, Charbonier A, Mozziconacci MJ, Birnbaum D, Chaffanet M, Vey N. Collette Y, et al. Among authors: castellano r. Blood Cancer J. 2015 Mar 13;5(3):e292. doi: 10.1038/bcj.2015.13. Blood Cancer J. 2015. PMID: 25768406 Free PMC article. No abstract available.
A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia.
Saland E, Boutzen H, Castellano R, Pouyet L, Griessinger E, Larrue C, de Toni F, Scotland S, David M, Danet-Desnoyers G, Vergez F, Barreira Y, Collette Y, Récher C, Sarry JE. Saland E, et al. Among authors: castellano r. Blood Cancer J. 2015 Mar 20;5(3):e297. doi: 10.1038/bcj.2015.19. Blood Cancer J. 2015. PMID: 25794133 Free PMC article.
167 results